For U.S Healthcare Professionals Only

ARCALYST (rilonacept) for injection

Coverage Finder

Check the Coverage Status for ARCALYST® (rilonacept) in Your Area

  

 

 

Source: Managed Markets Insight & Technology, LLC. Database as of June 2023.

This tool is intended to provide a summary of available coverage information for certain prescription drug plans and is not a guarantee of payment, coverage, or reimbursement for ARCALYST for any specific patient. Healthcare providers are responsible for determining coverage and reimbursement information and ensuring the accuracy and completeness of claim submissions for their patients. Coding, coverage, and reimbursement vary significantly by payer, patient, and setting of care and are subject to change. Contact insurer to confirm coverage of ARCALYST. Contact the Kiniksa OneConnect™ patient support program to learn about coverage support.

ARCALYST Has Low Out-of-Pocket Cost and High Commercial Access for Recurrent Pericarditis

 

≥95% of PA requests have been approved.*

Eligible commercially insured patients pay as little as $0 per month for ARCALYST treatment with the copay assistance program.†


*From approval in March 2021 to September 2024. 
†Based on final coverage approval.

Helping make treatment support simple for healthcare providers and patients

  • Dedicated point of contact for you and your patients 
  • Benefits verification 
  • Prior authorization support 
  • Financial assistance programs, if qualified 
  • Options for injection training 

The Kiniksa OneConnectTM patient support program is made up of a team of experienced individuals, known as Patient Access Leads, with knowledge of insurance plans and healthcare networks.

See All Program Services

Call 1-833-KINIKSA (1-833-546-4572), Option 1
Monday-Friday (8 AM - 8 PM ET)

Request to speak to a Clinical Sales Specialist

Indication

ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

  • Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
  • Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older. 
  • Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.

Important Safety Information

Warnings and Precautions

  • Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with another medication that works through inhibition of IL-1 or inhibition of tumor necrosis factor (TNF) is not recommended as this may increase the risk of serious infection. Serious, life-threatening infections have been reported in patients taking ARCALYST. Do not initiate treatment with ARCALYST in patients with an active or chronic infection.
  • Discontinue ARCALYST if a patient develops a serious infection.
  • It is possible that taking drugs such as ARCALYST that block IL-1 may increase the risk of tuberculosis (TB) or other atypical or opportunistic infections.
  • Although the impact of ARCALYST on infections and the development of malignancies is not known, treatment with immunosuppressants, including ARCALYST, may result in an increase in the risk of malignancies.
  • Hypersensitivity reactions associated with ARCALYST occurred in clinical trials. Discontinue ARCALYST and initiate appropriate therapy if a hypersensitivity reaction occurs. 
  • Increases in non-fasting lipid profile parameters occurred in patients treated with ARCALYST in clinical trials. Patients should be monitored for changes in their lipid profiles.
  • Since no data are available, avoid administration of live vaccines while patients are receiving ARCALYST. ARCALYST may interfere with the normal immune response to new antigens, so vaccines may not be effective in patients receiving ARCALYST. It is recommended that, prior to initiation of therapy with ARCALYST, patients receive all recommended vaccinations, as appropriate.

Adverse Reactions

  • In patients with CAPS or RP, the most common adverse reactions (≥10%) include injection-site reactions and upper respiratory tract infections.
  • In patients with DIRA, the most common adverse reactions (>10%) include upper respiratory tract infections, rash, otitis media, pharyngitis, and rhinorrhea.

Drug Interactions

  • In patients being treated with CYP450 substrates with narrow therapeutic indices, therapeutic monitoring of the effect or drug concentration should /pi.pdfbe performed, and the individual dose of the medicinal product may need to be adjusted.

For more information about ARCALYST, see full Prescribing Information.